We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

LGC Clinical Diagnostics

LGC Clinical Diagnostics is a leading provider of Quality Measurement Tools, biological materials, and reagents for t... read more Featured Products: More products

Download Mobile App





Technopath Presents Comprehensive Portfolio of Diagnostic Quality Solutions at AACC 2022

By LabMedica International staff writers
Posted on 26 Jul 2022
Print article
Image: IAMQC Transfer is the company’s latest connectivity solution (Photo courtesy of Technopath)
Image: IAMQC Transfer is the company’s latest connectivity solution (Photo courtesy of Technopath)

Technopath Clinical Diagnostics (Tipperary, Ireland) will be exhibiting at the annual AACC in Chicago, IL, July 25-28 as part of the LGC Clinical Diagnostics Group which represents the combined brands: Maine Standards, SeraCare, Technopath Clinical Diagnostics, and The Native Antigen Company. Technopath will present a comprehensive portfolio of catalogue and custom-developed diagnostic quality solutions and component materials at AACC 2022.

Technopath is showcasing the Multichem range of barcoded consolidated Quality Control (QC) materials combined with IAMQC informatics software that offer unique work-flow automation. By utilizing Multichem barcoded QC materials, laboratories can optimize their QC workflow and minimize handling errors. The company’s newest barcoded QC products can be recognized by the instrument, QC targets automatically downloaded to the instrument, and QC data automatically collected and reported in real-time. Technopath is also highlighting its Multichem range of independent consolidated QC materials. With an extensive list of analytes included in the Multichem range of quality control products, choice and flexibility are guaranteed for all customers. The company’s third-party quality control products include general clinical chemistry, immunoproteins, immunoassay, cardiac, urine chemistry, infectious disease, diabetes and other esoteric controls.

In addition, Technopath will demonstrate the IAMQC Infinity open QC data management solution that can complement and support the Multichem QC product range, and provides laboratory managers and technologists with a range of QC software tools to analyze their QC results in real-time. IAMQC Infinity is practical, graphical, user-definable and easy to use and provides laboratories with a centralized standardized approach to QC data management. Technopath’s IAMQC range of software products includes IAMQC Peer, an innovative, real-time, peer comparison software; IAMQC Transfer, a connectivity device (available as a virtual or physical device) that can communicate with Laboratory Information Systems (LIS), middleware, and to automated instrumentation and point of care platforms; and IAMQC Proficiency testing, a cloud-based portal used for automated submission of PT data and full PT scheme management for PT providers.
 

Related Links:
Technopath Clinical Diagnostics 

Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
Gold Member
Troponin T QC
Troponin T Quality Control
New
Gold Member
LEISHMANIA Test
LEISHMANIA ELISA
New
Auto 5-Part Differential Analyzer
XR-1000 Pure

Print article

Channels

Molecular Diagnostics

view channel
Image: Umbilical cord blood biomarkers may improve preterm infant care (Photo courtesy of Shutterstock)

Umbilical Cord Blood Test Could Identify Preterm Infants at Risk for Medical Complications

Advancements in medical technology and neonatology have significantly improved the care of prematurely born infants. However, these infants still face heightened risks for medical complications, such as... Read more

Immunology

view channel

3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response

Tumor heterogeneity presents a major obstacle in the development and treatment of cancer therapies, as patients' responses to the same drug can differ, and the timing of treatment significantly influences prognosis. Consequently, technologies that predict the effectiveness of anticancer treatments are essential in minimizing... Read more

Microbiology

view channel
Image: The Cytovale System isolates, images, and analyzes cells (Photo courtesy of Cytovale)

Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application

Sepsis is the leading cause of death and the most expensive condition treated in U.S. hospitals. The risk of death from sepsis increases by up to 8% for each hour that treatment is delayed, making early... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.